A preliminary clinical trial of a nasal formula of the anti-covid vaccine developed by the University of Oxford in collaboration with British lab AstraZeneca has failed, according to a statement released Tuesday.
Oxford estimates that this study is the first published on an adenovirus vector vaccine by spray nasal.
The researchers observed an antibody response in the nasal mucosa “in a minority of participants,” according to the University of Oxford.
The “systemic immune response to intranasal vaccination was also weaker than an intramuscular vaccination,” the statement added.
“This nasal spray didn’t work as well as we hoped,” said Sandy Douglas, an associate professor at the university who participated in the study.
The professor pointed out that a study in China had good results with a more complex vaporizer that launches the vaccine deeper into the lungs and therefore estimated that it is possible that a large part of the tested vaccine ended up in the digestive tract with the spray nose used.
The study used the same adenovirus vector used for the vaccine developed by Oxford with AstraZeneca, one of the first sera against Covid-19 to be introduced to the market at the height of the pandemic.
“Nasal and respiratory vaccination is one of the most promising ways to gain immunity” and “could end mild Covid-19 infections and virus transmission more effectively than injected vaccines,” noted Adam Ritchie, one of the leaders. .
It also has the benefit of “avoiding the use of a needle. Many parents know that” sprays are already being used for flu shots given to school-age children in some countries, including the UK,” he added.
The trial involved 30 people who had not been vaccinated before.
Source: DN
